肺癌微创手术的成本-效用分析:一项随机对照试验
该研究基于一项随机对照试验,对103例VATS和103例开胸肺叶切除术的Ⅰ期肺癌患者进行术后12个月的成本-效用分析。VATS是Ⅰ期肺癌肺叶切除术中相比开胸术具有成本效益的替代方案。
要点
- VATS组QALY增益差异为0.021(P=0.048),利于VATS。
- VATS住院时间更短(4.8 vs 6.7天,P=0.027)。
核心结论
- VATS是Ⅰ期肺癌肺叶切除术中相比开胸术具有成本效益的替代方案。
- 以质量调整生命年衡量的经济学结局VATS显著更好,且总体费用更低。
研究设计与样本
- 研究设计为术后前12个月的成本-效用分析,与一项VATS对比开胸行Ⅰ期肺癌肺叶切除术的临床随机对照试验一同进行,为期6年(2008-2014)。
- 共随机分配103例VATS患者和103例开胸患者。
- 所有健康相关费用从国家数据库(Statistics Denmark)检索,包括再入院、门诊就诊、处方药费用及全科医生、专科医生、物理治疗师、心理治疗师和脊椎按摩师咨询费用。
主要发现
- 52周随访期间获得的质量调整生命年差异为0.021(P=0.048,95%CI -0.04至-0.00015),利于VATS。
- 手术时间中位数开胸组更短(79 vs 100分钟;P<0.001)。
- 平均住院时间VATS组更短(4.8 vs 6.7天;P=0.027)。
临床怎么用
- 对于Ⅰ期肺癌行肺叶切除术,VATS在术后12个月内总体费用更低且QALY增益更优,可作为开胸术的成本效益替代方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Minimally invasive video-assisted thoracic surgery (VATS) was first introduced in the early 1990s. For decades, numerous non-randomized studies demonstrated advantages of VATS over thoracotomy with lower morbidity and shorter hospital stay, but only recently did a randomized trial document that VATS results in lower pain scores and better quality of life. Opposing arguments for VATS have always been increased costs and concerns about oncological adequacy. In this paper, we aim to investigate the cost-effectiveness of VATS. METHODS: The study was designed as a cost-utility analysis of the first 12 months following surgery and was performed together with a clinical randomized controlled trial of VATS versus thoracotomy for lobectomy of stage 1 lung cancer during a 6-year period (2008-2014). All health-related expenses were retrieved from a national database (Statistics Denmark) including hospital readmissions, outpatient clinic visits, prescription medication costs, consultations with general practitioners, specialists, physiotherapists, psychologists and chiropractors. RESULTS: One hundred and three VATS patients and 103 thoracotomy patients were randomized. Mean costs per patient operated by VATS were 103 108 Danish Kroner (Dkr) (€13 818) and 134 945 Dkr (€18 085) by thoracotomy, making the costs for VATS 31 837 Dkr (€4267) lower than thoracotomy (P < 0.001). The difference in quality-adjusted life years gained over 52 weeks of follow-up was 0.021 (P = 0.048, 95% confidence interval -0.04 to -0.00015) in favour of VATS. The median duration of the surgical procedure was shorter after thoracotomy (79 vs 100 min; P < 0.001). The mean length of hospitalization was shorter following VATS (4.8 vs 6.7 days; P = 0.027). The use of other resources was not significantly different between groups. The costs of resources were lower in the VATS group. This difference was primarily due to reduced costs of readmissions (VATS 29 247 Dkr vs thoracotomy 51 734 Dkr; P < 0.001) and costs of outpatient visits (VATS 51 412 Dkr vs thoracotomy 61 575 Dkr; P = 0.012). CONCLUSIONS: VATS is a cost-effective alternative to thoracotomy following lobectomy for stage 1 lung cancer. Economical outcomes as measured by quality-adjusted life years were significantly better and overall costs were lower for VATS. CLINICAL TRIAL REGISTRATION NUMBER: NCT01278888.
引用
- Bendixen M, Kronborg C, Jørgensen OD, et al. Cost-utility analysis of minimally invasive surgery for lung cancer: a randomized controlled trial. Eur J Cardiothorac Surg. 2019. PMID: 30838382. doi:10.1093/ejcts/ezz064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。